Ads
related to: vaso-occlusive sickle cell disease treatment- What Is LYFGENIA?
Learn About LYFGENIA As
A Treatment Option.
- Steps To Treatment
See A Breakdown Of
Treatment With LYFGENIA.
- How Does LYFGENIA Work?
See How It Works & The
Treatment Process.
- my bluebird support
Learn More About This Resource
For Patients On LYFGENIA.
- FAQs
Your LYFGENIA Questions. Answered.
Review Patient Information.
- Studies & Results
Review How LYFGENIA Was
Studied & The Results.
- What Is LYFGENIA?
Search results
Results From The WOW.Com Content Network
It is possible for a person to have both the gene for hemoglobin S (the form associated with sickle cell anemia) and the gene for hemoglobin C; this state is called hemoglobin SC disease, and is generally more severe than hemoglobin C disease, but milder than sickle cell anemia.
The acute chest syndrome is a vaso-occlusive crisis of the pulmonary vasculature commonly seen in people with sickle cell anemia. This condition commonly manifests with a new opacification of the lung(s) on a chest x-ray .
Treatment is the same as for patients with sickle cell disease. Patients may receive hydroxyurea to induce the protective effects of increased fetal hemoglobin production. They may also benefit from blood transfusions especially during vaso-occlusive crises.
Vaso-occlusive crisis is a common and painful complication of sickle cell disease that occurs when blood circulation is obstructed by sickled red blood cells (red cells are usually round and flexible, but sometimes many red cells in a person with sickle cell anemia will become rigid and crescent-shaped due to polymerization of hemoglobin). [11]
Splenic sequestration crisis is a life-threatening illness common in pediatric patients with homozygous sickle cell disease and beta thalassemia.Up to 30% of these children may develop splenic sequestration crisis with a mortality rate of up to 15%.
The company was founded as Genetix Pharmaceuticals in April 1992 by MIT faculty members Philippe Leboulch and Irving London. [7]In 2001, Walter Ogier was appointed chief executive officer of Genetix Pharmaceuticals, and the company was focused on the development of LentiglobinTM for the treatment of sickle cell disease and thalassemia major (beta-thalassemia), the two most globally prevalent ...
Ad
related to: vaso-occlusive sickle cell disease treatment